<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33118131</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>A Nitroalkene Benzoic Acid Derivative Targets Reactive Microglia and Prolongs Survival in an Inherited Model of ALS via NF-&#x3ba;B Inhibition.</ArticleTitle><Pagination><StartPage>309</StartPage><EndPage>325</EndPage><MedlinePgn>309-325</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-020-00953-z</ELocationID><Abstract><AbstractText>Motor neuron degeneration and neuroinflammation are the most striking pathological features of amyotrophic lateral sclerosis (ALS). ALS currently has no cure and approved drugs have only a modest clinically therapeutic effect in patients. Drugs targeting different deleterious inflammatory pathways in ALS appear as promising therapeutic alternatives. Here, we have assessed the potential therapeutic effect of an electrophilic nitroalkene benzoic acid derivative, (E)-4-(2-nitrovinyl) benzoic acid (BANA), to slow down paralysis progression when administered after overt disease onset in SOD1<sup>G93A</sup> rats. BANA exerted a significant inhibition of NF-&#x3ba;B activation in NF-&#x3ba;B reporter transgenic mice and microglial cell cultures. Systemic daily oral administration of BANA to SOD1<sup>G93A</sup> rats after paralysis onset significantly decreased microgliosis and astrocytosis, and significantly reduced the number of NF-&#x3ba;B-p65-positive microglial nuclei surrounding spinal motor neurons. Numerous microglia bearing nuclear NF-&#x3ba;B-p65 were observed in the surrounding of motor neurons in autopsy spinal cords from ALS patients but not in controls, suggesting ALS-associated microglia could be targeted by BANA. In addition, BANA-treated SOD1<sup>G93A</sup> rats after paralysis onset showed significantly ameliorated spinal motor neuron pathology as well as conserved neuromuscular junction innervation in the skeletal muscle, as compared to controls. Notably, BANA prolonged post-paralysis survival by ~30%, compared to vehicle-treated littermates. These data provide a rationale to therapeutically slow paralysis progression in ALS using small electrophilic compounds such as BANA, through a mechanism involving microglial NF-&#x3ba;B inhibition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ibarburu</LastName><ForeName>Sof&#xed;a</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurodegeneration Laboratory, Institut Pasteur de Montevideo, Mataojo, 2020, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Mari&#xe1;ngeles</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurodegeneration Laboratory, Institut Pasteur de Montevideo, Mataojo, 2020, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varela</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neurodegeneration Laboratory, Institut Pasteur de Montevideo, Mataojo, 2020, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Duarte</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Vascular Biology and Drug Development, INDICYO Program, Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingold</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Vascular Biology and Drug Development, INDICYO Program, Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departmento de Qu&#xed;mica Org&#xe1;nica, Facultad de Qu&#xed;mica, Universidad de la Rep&#xfa;blica, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Invernizzi</LastName><ForeName>Paulina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Vascular Biology and Drug Development, INDICYO Program, Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porcal</LastName><ForeName>Williams</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Laboratory of Vascular Biology and Drug Development, INDICYO Program, Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departmento de Qu&#xed;mica Org&#xe1;nica, Facultad de Qu&#xed;mica, Universidad de la Rep&#xfa;blica, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ar&#xe9;valo</LastName><ForeName>Ana Paula</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Transgenic and Experimental Animal Unit, Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perelmuter</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cell Biology Unit, Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bollati-Fogol&#xed;n</LastName><ForeName>Mariela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cell Biology Unit, Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escande</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Metabolic Diseases and Aging, INDICyO Program, Institut Pasteur Montevideo, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez</LastName><ForeName>Gloria V</ForeName><Initials>GV</Initials><AffiliationInfo><Affiliation>Laboratory of Vascular Biology and Drug Development, INDICYO Program, Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departmento de Qu&#xed;mica Org&#xe1;nica, Facultad de Qu&#xed;mica, Universidad de la Rep&#xfa;blica, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Birmingham Veterans Affairs Medical Center, Birmingham, AL, 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Si</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Birmingham Veterans Affairs Medical Center, Birmingham, AL, 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Yuri</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batthy&#xe1;ny</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Vascular Biology and Drug Development, INDICYO Program, Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbeito</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neurodegeneration Laboratory, Institut Pasteur de Montevideo, Mataojo, 2020, Montevideo, Uruguay. barbeito@pasteur.edu.uy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trias</LastName><ForeName>Emiliano</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7187-511X</Identifier><AffiliationInfo><Affiliation>Neurodegeneration Laboratory, Institut Pasteur de Montevideo, Mataojo, 2020, Montevideo, Uruguay. etrias@pasteur.edu.uy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BX001148</GrantID><Acronym>VA</Acronym><Agency>VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS111275</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS092651</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21NS111275-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX004419</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009579">Nitrobenzoates</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019073" MajorTopicYN="N">HT29 Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009579" MajorTopicYN="N">Nitrobenzoates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">BANA.</Keyword><Keyword MajorTopicYN="N">NF-&#x3ba;B-p65</Keyword><Keyword MajorTopicYN="N">microglia</Keyword></KeywordList><CoiStatement>MI is supported by EOLO PHARMA. GVL, CE, and CB hold shares in EOLO PHARMA S.A. and affiliates.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>29</Day><Hour>5</Hour><Minute>56</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33118131</ArticleId><ArticleId IdType="pmc">PMC8116482</ArticleId><ArticleId IdType="doi">10.1007/s13311-020-00953-z</ArticleId><ArticleId IdType="pii">10.1007/s13311-020-00953-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377(2):162&#x2013;72. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4(3):191&#x2013;206. doi: 10.1080/14660820310002601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820310002601</ArticleId><ArticleId IdType="pubmed">13129806</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing G, Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505&#x2013;12. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland DS, Liu J, She Y, Goad B, Maragakis NJ, Kim B, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS) Proc Natl Acad Sci U S A. 2002;99(3):1604&#x2013;9. doi: 10.1073/pnas.032539299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.032539299</ArticleId><ArticleId IdType="pmc">PMC122237</ArticleId><ArticleId IdType="pubmed">11818550</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Amarilla P, Olivera-Bravo S, Trias E, Cragnolini A, Martinez-Palma L, Cassina P, et al. Phenotypically aberrant astrocytes that promote motoneuron damage in a model of inherited amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2011;108(44):18126&#x2013;31. doi: 10.1073/pnas.1110689108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1110689108</ArticleId><ArticleId IdType="pmc">PMC3207668</ArticleId><ArticleId IdType="pubmed">22010221</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E, Diaz-Amarilla P, Olivera-Bravo S, Isasi E, Drechsel DA, Lopez N, et al. Phenotypic transition of microglia into astrocyte-like cells associated with disease onset in a model of inherited ALS. Front Cell Neurosci. 2013;7:274. doi: 10.3389/fncel.2013.00274.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00274</ArticleId><ArticleId IdType="pmc">PMC3871969</ArticleId><ArticleId IdType="pubmed">24399933</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E, Ibarburu S, Barreto-Nunez R, Barbeito L. Significance of aberrant glial cell phenotypes in pathophysiology of amyotrophic lateral sclerosis. Neurosci Lett. 2017;636:27&#x2013;31. doi: 10.1016/j.neulet.2016.07.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2016.07.052</ArticleId><ArticleId IdType="pubmed">27473942</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E, Ibarburu S, Barreto-Nunez R, Babdor J, Maciel TT, Guillo M, et al. Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J Neuroinflammation. 2016;13(1):177. doi: 10.1186/s12974-016-0620-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0620-9</ArticleId><ArticleId IdType="pmc">PMC4940876</ArticleId><ArticleId IdType="pubmed">27400786</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernandez M, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(1-2):5&#x2013;14. doi: 10.1080/21678421.2019.1632346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 2001;107(1):7&#x2013;11. doi: 10.1172/JCI11830..</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI11830.</ArticleId><ArticleId IdType="pmc">PMC198552</ArticleId><ArticleId IdType="pubmed">11134171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaltschmidt B, Kaltschmidt C. NF-kappaB in the nervous system. Cold Spring Harb Perspect Biol. 2009;1(3):a001271. doi: 10.1101/cshperspect.a001271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a001271</ArticleId><ArticleId IdType="pmc">PMC2773634</ArticleId><ArticleId IdType="pubmed">20066105</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Zhang L, Joo D, Sun SC. NF-kappaB signaling in inflammation. Signal Transduct Targete Therapy 2017;2. 10.1038/sigtrans.2017.23.</Citation></Reference><Reference><Citation>Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun L, Miranda CJ, et al. Microglia induce motor neuron death via the classical NF-kappaB pathway in amyotrophic lateral sclerosis. Neuron. 2014;81(5):1009&#x2013;23. doi: 10.1016/j.neuron.2014.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.013</ArticleId><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Dresselhaus EC, Meffert MK. Cellular Specificity of NF-kappaB Function in the Nervous System. Front Immunol. 2019;10:1043. doi: 10.3389/fimmu.2019.01043.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01043</ArticleId><ArticleId IdType="pmc">PMC6520659</ArticleId><ArticleId IdType="pubmed">31143184</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju Hwang C, Choi DY, Park MH, Hong JT. NF-kappaB as a Key Mediator of Brain Inflammation in Alzheimer's Disease. CNS Neurol Disord Drug Targets. 2019;18(1):3&#x2013;10. doi: 10.2174/1871527316666170807130011.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527316666170807130011</ArticleId><ArticleId IdType="pubmed">28782486</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, Phaneuf D, Dupre N, Petri S, Strong M, Kriz J, et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. J Exp Med. 2011;208(12):2429&#x2013;47. doi: 10.1084/jem.20111313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111313</ArticleId><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Sako W, Ito H, Yoshida M, Koizumi H, Kamada M, Fujita K, et al. Nuclear factor kappa B expression in patients with sporadic amyotrophic lateral sclerosis and hereditary amyotrophic lateral sclerosis with optineurin mutations. Clin Neuropathol. 2012;31(6):418&#x2013;23. doi: 10.5414/NP300493.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/NP300493</ArticleId><ArticleId IdType="pubmed">22762947</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoo NKH, Li L, Salvatore SR, Schopfer FJ, Freeman BA. Electrophilic fatty acid nitroalkenes regulate Nrf2 and NF-kappaB signaling:A medicinal chemistry investigation of structure-function relationships. Sci Rep. 2018;8(1):2295. doi: 10.1038/s41598-018-20460-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-20460-8</ArticleId><ArticleId IdType="pmc">PMC5797128</ArticleId><ArticleId IdType="pubmed">29396403</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui T, Schopfer FJ, Zhang J, Chen K, Ichikawa T, Baker PR, et al. Nitrated fatty acids: Endogenous anti-inflammatory signaling mediators. J Biol Chem. 2006;281(47):35686&#x2013;98. doi: 10.1074/jbc.M603357200..</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M603357200.</ArticleId><ArticleId IdType="pmc">PMC2169500</ArticleId><ArticleId IdType="pubmed">16887803</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Amarilla P, Miquel E, Trostchansky A, Trias E, Ferreira AM, Freeman BA, et al. Electrophilic nitro-fatty acids prevent astrocyte-mediated toxicity to motor neurons in a cell model of familial amyotrophic lateral sclerosis via nuclear factor erythroid 2-related factor activation. Free Radic Biol Med. 2016;95:112&#x2013;20. doi: 10.1016/j.freeradbiomed.2016.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2016.03.013</ArticleId><ArticleId IdType="pmc">PMC4867302</ArticleId><ArticleId IdType="pubmed">27012417</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Duarte J, Dapueto R, Galliussi G, Turell L, Kamaid A, Khoo NKH, et al. Electrophilic nitroalkene-tocopherol derivatives: synthesis, physicochemical characterization and evaluation of anti-inflammatory signaling responses. Sci Rep. 2018;8(1):12784. doi: 10.1038/s41598-018-31218-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-31218-7</ArticleId><ArticleId IdType="pmc">PMC6109136</ArticleId><ArticleId IdType="pubmed">30143727</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Duarte J, Galliussi G, Dapueto R, Rossello J, Malacrida L, Kamaid A, et al. A novel nitroalkene-alpha-tocopherol analogue inhibits inflammation and ameliorates atherosclerosis in Apo E knockout mice. Br J Pharmacol. 2019;176(6):757&#x2013;72. doi: 10.1111/bph.14561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14561</ArticleId><ArticleId IdType="pmc">PMC6393233</ArticleId><ArticleId IdType="pubmed">30588602</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridges JW, French MR, Smith RL, Williams RT. The fate of benzoic acid in various species. Biochem J. 1970;118(1):47&#x2013;51. doi: 10.1042/bj1180047..</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj1180047.</ArticleId><ArticleId IdType="pmc">PMC1179077</ArticleId><ArticleId IdType="pubmed">4990586</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonard JV, Morris AA. Urea cycle disorders. Semin Neonatol. 2002;7(1):27&#x2013;35. doi: 10.1053/siny.2001.0085..</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/siny.2001.0085.</ArticleId><ArticleId IdType="pubmed">12069536</ArticleId></ArticleIdList></Reference><Reference><Citation>Modi KK, Roy A, Brahmachari S, Rangasamy SB, Pahan K. Cinnamon and Its Metabolite Sodium Benzoate Attenuate the Activation of p21rac and Protect Memory and Learning in an Animal Model of Alzheimer's Disease. PLoS One. 2015;10(6):e0130398. doi: 10.1371/journal.pone.0130398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0130398</ArticleId><ArticleId IdType="pmc">PMC4478015</ArticleId><ArticleId IdType="pubmed">26102198</ArticleId></ArticleIdList></Reference><Reference><Citation>Khasnavis S, Pahan K. Sodium benzoate, a metabolite of cinnamon and a food additive, upregulates neuroprotective Parkinson disease protein DJ-1 in astrocytes and neurons. J Neuroimmune Pharmacol. 2012;7(2):424&#x2013;35. doi: 10.1007/s11481-011-9286-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-011-9286-3</ArticleId><ArticleId IdType="pmc">PMC3189510</ArticleId><ArticleId IdType="pubmed">21701815</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998;396(6706):77&#x2013;80. doi: 10.1038/23948..</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/23948.</ArticleId><ArticleId IdType="pubmed">9817203</ArticleId></ArticleIdList></Reference><Reference><Citation>Grilli M, Pizzi M, Memo M, Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science. 1996;274(5291):1383&#x2013;5. doi: 10.1126/science.274.5291.1383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5291.1383</ArticleId><ArticleId IdType="pubmed">8910280</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht P, Bouchachia I, Goebels N, Henke N, Hofstetter HH, Issberner A, et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation. 2012;9:163. doi: 10.1186/1742-2094-9-163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-9-163</ArticleId><ArticleId IdType="pmc">PMC3419128</ArticleId><ArticleId IdType="pubmed">22769044</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SA, White JA, Chowdhury R, Gales DN, Tameru B, Tiwari AK, et al. Effects of consumption of whole grape powder on basal NF-kappaB signaling and inflammatory cytokine secretion in a mouse model of inflammation. J Nutr Intermed Metabol. 2018;11:1&#x2013;8. doi: 10.1016/j.jnim.2017.11.002..</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jnim.2017.11.002.</ArticleId><ArticleId IdType="pmc">PMC5858739</ArticleId><ArticleId IdType="pubmed">29568797</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastropietro G, Tiscornia I, Perelmuter K, Astrada S, Bollati-Fogolin M. HT-29 and Caco-2 reporter cell lines for functional studies of nuclear factor kappa B activation. Mediat Inflamm. 2015;2015:860534. doi: 10.1155/2015/860534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/860534</ArticleId><ArticleId IdType="pmc">PMC4377483</ArticleId><ArticleId IdType="pubmed">25861164</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen GM, Gowing G, Latter J, Chen M, Vit JP, Staggenborg K, et al. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J Neurosci. 2014;34(47):15587&#x2013;600. doi: 10.1523/JNEUROSCI.2037-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2037-14.2014</ArticleId><ArticleId IdType="pmc">PMC4298650</ArticleId><ArticleId IdType="pubmed">25411487</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E, Ibarburu S, Barreto-Nunez R, Varela V, Moura IC, Dubreuil P, et al. Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS. JCI Insight 2017;2(20). 10.1172/jci.insight.95934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5846907</ArticleId><ArticleId IdType="pubmed">29046475</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs M, Trias E, Varela V, Ibarburu S, Beckman JS, Moura IC, et al. CD34 Identifies a Subset of Proliferating Microglial Cells Associated with Degenerating Motor Neurons in ALS. Int J Mol Sci 2019;20(16). 10.3390/ijms20163880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6720880</ArticleId><ArticleId IdType="pubmed">31395804</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Ryder J, Mekhael L, Rd H, Mathers S, Needham M, et al. Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant) Medicine. 2020;99(6):e18904. doi: 10.1097/MD.0000000000018904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000018904</ArticleId><ArticleId IdType="pmc">PMC7015658</ArticleId><ArticleId IdType="pubmed">32028398</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahmachari S, Jana A, Pahan K. Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses. J Immunol. 2009;183(9):5917&#x2013;27. doi: 10.4049/jimmunol.0803336.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0803336</ArticleId><ArticleId IdType="pmc">PMC2862570</ArticleId><ArticleId IdType="pubmed">19812204</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E, Beilby PR, Kovacs M, Ibarburu S, Varela V, Barreto-Nunez R, et al. Emergence of Microglia Bearing Senescence Markers During Paralysis Progression in a Rat Model of Inherited ALS. Front Aging Neurosci. 2019;11:42. doi: 10.3389/fnagi.2019.00042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00042</ArticleId><ArticleId IdType="pmc">PMC6403180</ArticleId><ArticleId IdType="pubmed">30873018</ArticleId></ArticleIdList></Reference><Reference><Citation>Leigh PN, Whitwell H, Garofalo O, Buller J, Swash M, Martin JE, et al. Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain J Neurol. 1991;114(Pt 2):775&#x2013;88. doi: 10.1093/brain/114.2.775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/114.2.775</ArticleId><ArticleId IdType="pubmed">1646064</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH., Jr Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol. 1997;42(4):644&#x2013;54. doi: 10.1002/ana.410420416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410420416</ArticleId><ArticleId IdType="pubmed">9382477</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MC, Kim SJ, Kim DS, Jeon YD, Park SJ, Lee HS, et al. Vanillic acid inhibits inflammatory mediators by suppressing NF-kappaB in lipopolysaccharide-stimulated mouse peritoneal macrophages. Immunopharmacol Immunotoxicol. 2011;33(3):525&#x2013;32. doi: 10.3109/08923973.2010.547500.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08923973.2010.547500</ArticleId><ArticleId IdType="pubmed">21250779</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P, Julien JP, Kriz J. Early-stage treatment with Withaferin A reduces levels of misfolded superoxide dismutase 1 and extends lifespan in a mouse model of amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12(1):217&#x2013;33. doi: 10.1007/s13311-014-0311-0..</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0311-0.</ArticleId><ArticleId IdType="pmc">PMC4322065</ArticleId><ArticleId IdType="pubmed">25404049</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, Baloh RH. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137(5):715&#x2013;30. doi: 10.1007/s00401-018-1933-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1933-9</ArticleId><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Shruthi K, Reddy SS, Chitra PS, Reddy GB. Ubiquitin-proteasome system and ER stress in the brain of diabetic rats. J Cell Biochem. 2019;120(4):5962&#x2013;73. doi: 10.1002/jcb.27884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.27884</ArticleId><ArticleId IdType="pubmed">30317658</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantuma NP, Bott LC. The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution. Front Mol Neurosci. 2014;7:70. doi: 10.3389/fnmol.2014.00070.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2014.00070</ArticleId><ArticleId IdType="pmc">PMC4117186</ArticleId><ArticleId IdType="pubmed">25132814</ArticleId></ArticleIdList></Reference><Reference><Citation>Estevez AG, Spear N, Manuel SM, Radi R, Henderson CE, Barbeito L, et al. Nitric oxide and superoxide contribute to motor neuron apoptosis induced by trophic factor deprivation. J Neurosci. 1998;18(3):923&#x2013;31. doi: 10.1523/JNEUROSCI.18-03-00923.1998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.18-03-00923.1998</ArticleId><ArticleId IdType="pmc">PMC6792767</ArticleId><ArticleId IdType="pubmed">9437014</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton SA, Rezaie T, Nutter A, Lopez KM, Parker J, Kosaka K, et al. Therapeutic advantage of pro-electrophilic drugs to activate the Nrf2/ARE pathway in Alzheimer's disease models. Cell Death Dis. 2016;7(12):e2499. doi: 10.1038/cddis.2016.389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2016.389</ArticleId><ArticleId IdType="pmc">PMC5261011</ArticleId><ArticleId IdType="pubmed">27906174</ArticleId></ArticleIdList></Reference><Reference><Citation>Schopfer FJ, Vitturi DA, Jorkasky DK, Freeman BA. Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases. Nitric Oxide Biol Chem. 2018;79:31&#x2013;7. doi: 10.1016/j.niox.2018.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.niox.2018.06.006</ArticleId><ArticleId IdType="pmc">PMC6280193</ArticleId><ArticleId IdType="pubmed">29944935</ArticleId></ArticleIdList></Reference><Reference><Citation>Bright JJ, Kanakasabai S, Chearwae W, Chakraborty S. PPAR Regulation of Inflammatory Signaling in CNS Diseases. PPAR Res. 2008;2008:658520. doi: 10.1155/2008/658520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2008/658520</ArticleId><ArticleId IdType="pmc">PMC2490815</ArticleId><ArticleId IdType="pubmed">18670616</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona JC, Duchen MR. PPARgamma as a therapeutic target to rescue mitochondrial function in neurological disease. Free Radic Biol Med. 2016;100:153&#x2013;63. doi: 10.1016/j.freeradbiomed.2016.06.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2016.06.023</ArticleId><ArticleId IdType="pmc">PMC5145801</ArticleId><ArticleId IdType="pubmed">27352979</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T, Okamoto SI, Cui J, Watanabe Y, Furuta K, Suzuki M, et al. Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers. Proc Natl Acad Sci U S A. 2006;103(3):768&#x2013;73. doi: 10.1073/pnas.0505723102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0505723102</ArticleId><ArticleId IdType="pmc">PMC1334635</ArticleId><ArticleId IdType="pubmed">16407140</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan M, Lahiri DK. Significance of NF-kappaB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer's disease and multiple sclerosis. Expert Opin Ther Targets. 2015;19(4):471&#x2013;87. doi: 10.1517/14728222.2014.989834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728222.2014.989834</ArticleId><ArticleId IdType="pmc">PMC5873291</ArticleId><ArticleId IdType="pubmed">25652642</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomprezzi R. Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview. Ther Adv Neurol Disord. 2015;8(1):20&#x2013;30. doi: 10.1177/1756285614564152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756285614564152</ArticleId><ArticleId IdType="pmc">PMC4286944</ArticleId><ArticleId IdType="pubmed">25584071</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlstrom KE, Ewing E, Granqvist M, Gyllenberg A, Aeinehband S, Enoksson SL, et al. Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes. Nat Commun. 2019;10(1):3081. doi: 10.1038/s41467-019-11139-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11139-3</ArticleId><ArticleId IdType="pmc">PMC6626021</ArticleId><ArticleId IdType="pubmed">31300673</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills EA, Ogrodnik MA, Plave A, Mao-Draayer Y. Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis. Front Neurol. 2018;9:5. doi: 10.3389/fneur.2018.00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00005</ArticleId><ArticleId IdType="pmc">PMC5787128</ArticleId><ArticleId IdType="pubmed">29410647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastrati I, Siklos MI, Calderon-Gierszal EL, El-Shennawy L, Georgieva G, Thayer EN, et al. Dimethyl Fumarate Inhibits the Nuclear Factor kappaB Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein. J Biol Chem. 2016;291(7):3639&#x2013;47. doi: 10.1074/jbc.M115.679704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.679704</ArticleId><ArticleId IdType="pmc">PMC4751401</ArticleId><ArticleId IdType="pubmed">26683377</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E, King PH, Si Y, Kwon Y, Varela V, Ibarburu S, et al. Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS. JCI Insight 2018;3(19). 10.1172/jci.insight.123249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6237484</ArticleId><ArticleId IdType="pubmed">30282815</ArticleId></ArticleIdList></Reference><Reference><Citation>Graves MC, Fiala M, Dinglasan LA, Liu NQ, Sayre J, Chiappelli F, et al. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(4):213&#x2013;9. doi: 10.1080/14660820410020286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820410020286</ArticleId><ArticleId IdType="pubmed">15799549</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagano S, Takahashi Y, Yamamoto K, Masutani H, Fujiwara N, Urushitani M, et al. A cysteine residue affects the conformational state and neuronal toxicity of mutant SOD1 in mice: relevance to the pathogenesis of ALS. Hum Mol Genet. 2015;24(12):3427&#x2013;39. doi: 10.1093/hmg/ddv093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv093</ArticleId><ArticleId IdType="pubmed">25762155</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JR, Trias E, Beilby PR, Lopez NI, Labut EM, Bradford CS, et al. Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD(G93A) mice co-expressing the Copper-Chaperone-for-SOD. Neurobiol Dis. 2016;89:1&#x2013;9. doi: 10.1016/j.nbd.2016.01.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.01.020</ArticleId><ArticleId IdType="pmc">PMC4785045</ArticleId><ArticleId IdType="pubmed">26826269</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx. 2005;2(1):54&#x2013;62. doi: 10.1602/neurorx.2.1.54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1602/neurorx.2.1.54</ArticleId><ArticleId IdType="pmc">PMC539320</ArticleId><ArticleId IdType="pubmed">15717057</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Sanberg PR. Blood-CNS Barrier Impairment in ALS patients versus an animal model. Front Cell Neurosci. 2014;8:21. doi: 10.3389/fncel.2014.00021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00021</ArticleId><ArticleId IdType="pmc">PMC3910123</ArticleId><ArticleId IdType="pubmed">24550780</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sengillo JD, Sagare AP, Zhao Z, Ma Q, Zuniga E, et al. Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci U S A. 2014;111(11):E1035&#x2013;42. doi: 10.1073/pnas.1401595111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1401595111</ArticleId><ArticleId IdType="pmc">PMC3964055</ArticleId><ArticleId IdType="pubmed">24591593</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansson D, Rustenhoven J, Feng S, Hurley D, Oldfield RL, Bergin PS, et al. A role for human brain pericytes in neuroinflammation. J Neuroinflammation. 2014;11:104. doi: 10.1186/1742-2094-11-104..</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-104.</ArticleId><ArticleId IdType="pmc">PMC4105169</ArticleId><ArticleId IdType="pubmed">24920309</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>